Gleevec Buyers Say 1st Circ.'s Dismissal Misread Patent Law
Buyers of the leukemia drug Gleevec urged a First Circuit panel on Friday to rehear its decision affirming the dismissal of a proposed class action accusing Novartis of using sham litigation...To view the full article, register now.
Already a subscriber? Click here to view full article